{"id":"bexagliflozin-tablets","safety":{"commonSideEffects":[{"rate":null,"effect":"Genital mycotic infections"},{"rate":null,"effect":"Urinary tract infections"},{"rate":null,"effect":"Polyuria"},{"rate":null,"effect":"Polydipsia"}]},"_chembl":{"chemblId":"CHEMBL1808388","moleculeType":"Small molecule","molecularWeight":"464.94"},"_dailymed":{"setId":"f918583d-0337-40da-8da1-1e1320b8d027","title":"BEXACAT (BEXAGLIFLOZIN TABLETS) TABLET [ELANCO US INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"SGLT2 inhibitors block the reabsorption of filtered glucose in the proximal tubule of the nephron, allowing excess glucose to be excreted in the urine. This mechanism reduces blood glucose independently of insulin secretion and has additional cardiovascular and renal protective effects. Bexagliflozin is a selective SGLT2 inhibitor developed for type 2 diabetes management.","oneSentence":"Bexagliflozin inhibits sodium-glucose cotransporter 2 (SGLT2) in the kidney to increase urinary glucose excretion and lower blood glucose levels.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T03:23:22.392Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT03514641","phase":"PHASE2, PHASE3","title":"An Integrated Assessment of the Safety and Effectiveness of Bexagliflozin for the Management of Essential Hypertension","status":"COMPLETED","sponsor":"Theracos","startDate":"2017-10-18","conditions":"Essential Hypertension","enrollment":673},{"nctId":"NCT03197324","phase":"PHASE1","title":"Bexagliflozin Drug/Drug Interaction Study With Digoxin","status":"COMPLETED","sponsor":"Theracos","startDate":"2017-07-24","conditions":"Type2 Diabetes Mellitus","enrollment":20},{"nctId":"NCT02956044","phase":"PHASE1","title":"Interaction of Bexagliflozin With Metformin, Glimepiride and Sitagliptin","status":"COMPLETED","sponsor":"Theracos","startDate":"2016-11","conditions":"Type2 Diabetes Mellitus","enrollment":54},{"nctId":"NCT02558296","phase":"PHASE3","title":"Bexagliflozin Efficacy and Safety Trial","status":"COMPLETED","sponsor":"Theracos","startDate":"2015-10","conditions":"Type 2 Diabetes Mellitus","enrollment":1700},{"nctId":"NCT03259789","phase":"PHASE3","title":"Safety and Efficacy of Bexagliflozin Compared to Placebo as Add-on Therapy to Metformin in Type 2 Diabetes Subjects","status":"COMPLETED","sponsor":"Theracos","startDate":"2017-11-28","conditions":"Type2 Diabetes Mellitus","enrollment":351},{"nctId":"NCT03296800","phase":"PHASE1","title":"Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects","status":"COMPLETED","sponsor":"Theracos","startDate":"2017-09-27","conditions":"Type 2 Diabetes Mellitus","enrollment":48},{"nctId":"NCT02836873","phase":"PHASE3","title":"Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment","status":"COMPLETED","sponsor":"Theracos","startDate":"2016-09-23","conditions":"Type 2 Diabetes Mellitus","enrollment":312},{"nctId":"NCT02390050","phase":"PHASE2","title":"A Dose Range Finding Study to Evaluate the Effect of Bexagliflozin Tablets in Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Theracos","startDate":"2015-05-12","conditions":"Diabetes Mellitus, Type 2","enrollment":292},{"nctId":"NCT02715258","phase":"PHASE3","title":"Safety and Efficacy of Bexagliflozin as Monotherapy in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Theracos","startDate":"2016-03","conditions":"Type 2 Diabetes Mellitus","enrollment":210},{"nctId":"NCT03115112","phase":"PHASE3","title":"Safety and Efficacy of Bexagliflozin Compared to Sitagliptin as Add-on Therapy to Metformin in Type 2 Diabetes Subjects","status":"COMPLETED","sponsor":"Theracos","startDate":"2017-10-12","conditions":"Type 2 Diabetes Mellitus","enrollment":386},{"nctId":"NCT02820298","phase":"PHASE1","title":"Study to Evaluate the Effects of a High-Fat Meal on Bexagliflozin in Healthy Subjects","status":"COMPLETED","sponsor":"Theracos","startDate":"2016-06-20","conditions":"Type 2 Diabetes Mellitus","enrollment":25},{"nctId":"NCT03557658","phase":"PHASE1","title":"Safety and Efficacy of Bexagliflozin in Subjects With Moderate Hepatic Impairment","status":"COMPLETED","sponsor":"Theracos","startDate":"2018-07-26","conditions":"Type2 Diabetes Mellitus","enrollment":16},{"nctId":"NCT03167411","phase":"PHASE1","title":"Bexagliflozin Drug/Drug Interaction Study With Exenatide Injection","status":"COMPLETED","sponsor":"Theracos","startDate":"2017-05-24","conditions":"Type2 Diabetes Mellitus","enrollment":20},{"nctId":"NCT02769481","phase":"PHASE3","title":"Safety and Efficacy of Bexagliflozin Compared to Glimepiride as Add-on Therapy to Metformin in Type 2 Diabetes Subjects","status":"COMPLETED","sponsor":"Theracos","startDate":"2016-08-15","conditions":"Type 2 Diabetes Mellitus","enrollment":426},{"nctId":"NCT03417076","phase":"PHASE1","title":"Absolute Bioavailability Study With Bexagliflozin","status":"WITHDRAWN","sponsor":"Theracos","startDate":"2018-08-01","conditions":"Type 2 Diabetes Mellitus","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Code name: EGT0001442"],"phase":"marketed","status":"active","brandName":"Bexagliflozin tablets","genericName":"Bexagliflozin tablets","companyName":"Theracos","companyId":"theracos","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bexagliflozin inhibits sodium-glucose cotransporter 2 (SGLT2) in the kidney to increase urinary glucose excretion and lower blood glucose levels. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}